Home | Emory University

Infectious Diseases Clinical Research Consortium (IDCRC)

Infectious Diseases Clinical Research Consortium

Slide 1:
Slide 2:
Slide 3:

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

About

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies

IDCRC study explores challenges faced by early-stage faculty in Infectious Diseases and how to address these issues

The coronavirus disease 2019 (COVID-19) pandemic and associated increase in family care responsibilities resulted in unsustainable personal and professional workloads for infectious diseases (ID) faculty on the front lines. By investing in systemic change to make the ID workforce more equitable, we can embody the shared ideals of diversity and inclusion and prepare for the next pandemic.

IDCRC mentees use personal experience in infectious diseases to reflect on how the pandemic posed specific challenges with regard to career and family

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN

COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

IDCRC Sites Across the Nation

View World Map

News from VTEU Trials

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine

AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

IDCRC Leadership Group

IDCRC Vaccine & Treatment Evaluation Units (VTEUs)

IDCRC Concept Quick Stats

ICP Status

Approved: 46
Administratively Not Supported: 23
Revise & Resubmit: 5
Withdrawn: 12
Liaisons: 0
EWGs: 2
Not Approved: 43
EMT: 1
Other: 8

EWG Assignment

COVID: 86
Respiratory: 15
STI: 12
Malaria/Topical Diseases: 8
Enteric Infections: 6
Emerging Infections: 7
Mpox: 6

ECP

Prioritization/Protocol Development: 12
IDCRC Concept Study Underway: 4
Moved forward through other processes: 4
Pending: 5
Not approved: 9
In Process: 3
Hold: 5
Withdrawn/Halted: 7
Note: Protocols Transitioned to IDCRC for Protocol Implementation: 5
Other studies in process not from IDCRC concepts (MOMI-VAX, Moderna Pediatric, Moderna Variant, Moderna Boost): 5

IDCRC Citation Statement

Please include the following citation in any publications resulting from direct or indirect IDCRC support:

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

Publications